Last $37.61 USD
Change Today +0.76 / 2.06%
Volume 76.2K
KYTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

kythera biopharmaceuticals i (KYTH) Snapshot

Open
$36.98
Previous Close
$36.85
Day High
$37.74
Day Low
$36.85
52 Week High
02/26/14 - $56.36
52 Week Low
09/3/13 - $25.69
Market Cap
852.7M
Average Volume 10 Days
126.3K
EPS TTM
$-5.32
Shares Outstanding
22.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KYTHERA BIOPHARMACEUTICALS I (KYTH)

Related News

No related news articles were found.

kythera biopharmaceuticals i (KYTH) Related Businessweek News

No Related Businessweek News Found

kythera biopharmaceuticals i (KYTH) Details

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market. It is developing ATX-101, is an injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The company also has various additional research programs around therapeutic intervention for hair loss; and maintains active research interest in hair and fat biology, pigmentation modulation, and facial contouring. KYTHERA Biopharmaceuticals, Inc. has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Calabasas, California.

83 Employees
Last Reported Date: 08/7/14
Founded in 2004

kythera biopharmaceuticals i (KYTH) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $448.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $312.7K
Chief Medical Officer
Total Annual Compensation: $348.8K
Compensation as of Fiscal Year 2013.

kythera biopharmaceuticals i (KYTH) Key Developments

KYTHERA Biopharmaceuticals Submits New Drug Submission to Health Canada for ATX-101

KYTHERA Biopharmaceuticals, Inc. announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational drug, ATX-101 (deoxycholic acid), as an injectable treatment for the reduction of submental fat. The NDS is supported by results from two pivotal Phase III trials, REFINE-1 and REFINE-2, which were reported in late 2013. In these trials, the majority of ATX-101 patients had a visible reduction in fat under the chin and reported significant improvement in the visual and emotional impact of treatment. The NDS submission is the first of multiple ex-U.S. regulatory submissions that KYTHERA plans to make by the second quarter of 2015.

Kythera Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Kythera Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $18.326 million compared to $11.740 million a year ago. Interest income was $51,000 compared to $35,000 a year ago. Net loss was $19.482 million or $0.86 per basic and diluted share compared to $12.258 million or $0.67 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $87.184 million compared to $25.499 million a year ago. Interest income was $118,000 compared to $63,000 a year ago. Net loss was $88.927 million or $4.00 per basic and diluted share compared to $26.384 million or $1.44 per basic and diluted share a year ago. Non-GAAP net loss was $36.170 million compared to $26.384 million a year ago.

Kythera Biopharmaceuticals, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Kythera Biopharmaceuticals, Inc. announced that they will report Q2, 2014 results on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KYTH:US $37.61 USD +0.76

KYTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KYTH.
View Industry Companies
 

Industry Analysis

KYTH

Industry Average

Valuation KYTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYTHERA BIOPHARMACEUTICALS I, please visit www.kytherabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.